Product news

Share this article:
Genzyme announced an FDA marketing approval for Mozobil (plerixafor injection), a drug to be used in combination with a granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. The product also received an orphan drug designation. 
 
Following an FDA safety alert on oral sodium phosphates (OSP), C.B. Fleet has announced a voluntary recall of over-the-counter products Fleet Phospho-soda and Fleet Phospho-soda EZ-Prep Bowel Cleansing System. The FDA recommended that these products not be used for bowel cleansing. Two prescription OSPs manufactured by Salix Pharmaceuticals, Visicol and OsmoPrep, were given box warnings related to the risk of acute kidney injury.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.